GlassScriptPhysician profile
Nathaniel L Jones
NPI 1255645594
$24,581.22
in general payments reported to CMS, 2019-2025
51 companies · $9,212 in 2025
The $9,212 reported for 2025 was more than what 90% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2021: $2,055 · 2022: $1,498 · 2023: $2,570 · 2024: $7,258 · 2025: $9,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $5,871 · Travel and Lodging: $1,009 · Gift: $49.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,110.84 |
| Food and Beverage | $5,871.05 |
| Travel and Lodging | $1,009.22 |
| Gift | $49.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,074.23 | 2019-2025 | Da Vinci Surgical System |
| Seagen INC. | $2,150.24 | 2021-2023 | Padcev |
| Janssen Biotech, INC. | $480.43 | 2022-2025 | Erleada, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $478.01 | 2022-2025 | Enhertu, Injectafer |
| Eisai INC. | $422.93 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $365.73 | 2022-2025 | Libtayo, Lynozyfic |
| Astrazeneca Pharmaceuticals LP | $343.00 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $330.56 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Incyte Corporation | $320.51 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $318.85 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Novartis Pharmaceuticals Corporation | $248.98 | 2022-2025 | |
| Exelixis INC. | $203.97 | 2022-2025 | Cabometyx |
| Amgen INC. | $176.37 | 2022 | |
| Baxter Healthcare | $174.84 | 2021-2025 | Perclot |
| Genzyme Corporation | $151.40 | 2023-2025 |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.